All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olipudase alfa
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
Details:
Olipudase alfa is the first and only investigational enzyme replacement therapy in late-stage development for the treatment of ASMD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leriglitazone
Therapeutic Area: Genetic Disease Product Name: MIN-102
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 30, 2020
Details:
The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LYS-SAF302
Therapeutic Area: Genetic Disease Product Name: AAVrh10-h.SGSH
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
AAVance clinical trial is a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis. The company remains committed to the LYS-SAF302 development program and the Sanfilippo patient community.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Genetic Disease Product Name: MTP-131
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
The poster titled "TAZPOWER Analysis: Elamipretide Significantly Improves Disease Symptomatology versus Natural History Controls in Barth Syndrome," shows the importance of longitudinal natural history data in understanding and validating clinical trial outcomes for Barth.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LYS-SAF302
Therapeutic Area: Genetic Disease Product Name: AAVrh10-h.SGSH
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Company has announced death of a patient in the AAVance study , a phase 2/3 international clinical study evaluating gene therapy treatment of Mucopolysaccharidosis type IIIA (MPS IIIA, known as Sanfilippo Syndrome type A) .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: Zygel
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
New data demonstrate that in patients diagnosed with FXS with a fully methylated FMR1 gene significantly more patients who received Zygel achieved a clinically meaningful improvement in their behavioral symptoms compared to patients who received placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ARO-AAT
Therapeutic Area: Genetic Disease Product Name: ARO-AAT
Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $1,040.0 million Upfront Cash: $300.0 million
Deal Type: Licensing Agreement October 08, 2020
Details:
Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the U.S under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global marketing strategy and receive an exclusive license to commercialize ARO-AAT.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leriglitazone
Therapeutic Area: Genetic Disease Product Name: MIN-102
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sperogenix Therapeutics
Deal Size: $78.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 23, 2020
Details:
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risdiplam
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $650.0 million Upfront Cash: $650.0 million
Deal Type: Agreement July 20, 2020
Details:
Risdiplam, to be marketed by Roche, is an investigational, orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arimoclomol
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Orphazyme has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
